BC

Birchview Capital, LP

Diversified strategySector-focusedMomentum follower

Total reported value

$175.7M

Reporting period: 2026-03-31 · Number of holdings: 73

Birchview Capital, LP disclosed 73 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $175.7M and a quarterly turnover rate of 41.0%.

Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "B"

Personality snowflake

Concentration
21.7
Portfolio Stability
41.04
Momentum/Contrarian
100
Sector conviction
100
Diversification
100
Sizing Uniformity
82.68

Recent moves

  • Trim OLMA

    -18.6%　-$3.5M

  • Trim CSTL

    -84.0%　-$2.8M

  • Add NTLA

    +41.2%　$2.9M

  • Add 09075X108

    0.0%　$2.2M

  • Add OVV

    0.0%　$2.2M

  • Add KLAC

    -9.1%　$2.7M

Holdings Map

New buyAddUnchangedTrim

Top 10 holdings by weight

Full holdings list this quarter

#TickerIssuerAsset SubclassWeightWeight ChangeShares Change4Q Trend
1KLACKla CORPStock-Tech16.67%+1.10%-9.14%
2BMYBristol-myers Squibb CoStock-Healthcare10.57%+1.01%+1.13%
3CMPXCompass Therapeutics INCStock-Other4.41%-0.60%-7.98%
4LRCXLam Research CORPStock-Tech4.38%+0.34%-10.73%
5STOKStoke Therapeutics INCStock-Other3.89%-0.94%-19.23%
6OVVOvintiv INCStock-Energy3.63%+1.16%—
7NTLAIntellia Therapeutics INCStock-Other3.25%+1.59%+41.22%
8GPCRStructure Therapeutics INCStock-Other2.74%-0.92%+11.11%
9SLDBSolid Biosciences INCStock-Other2.57%+0.24%-11.33%
10PRTAProthena Corporation plcStock-Other2.48%—+1.81%
11✓ Biodesix INCStock-Other2.37%+1.23%—
12ACADAcadia Pharmaceuticals INCStock-Healthcare2.17%-0.50%—
13PTGXProtagonist Therapeutics INCStock-Other2.10%-0.71%-36.36%
14NBIXNeurocrine Biosciences INCStock-Healthcare2.04%——
15OLMAOlema Pharmaceuticals INCStock-Other1.86%-2.08%-18.59%
16RLMDRelmada Therapeutics INCStock-Other1.62%+1.62%NEW
17OCULOcular Therapeutix INCStock-Other1.54%+1.54%NEW
18UTHRUnited Therapeutics CORPStock-Healthcare1.52%+0.66%+50.00%
19NKTRNektar TherapeuticsStock-Other1.27%+0.50%—
20CLDXCelldex Therapeutics INCStock-Other1.27%+1.27%NEW
21NVCRNovoCure LimitedStock-Healthcare1.26%—+33.02%
22EQTEqt CORPStock-Energy1.25%——
23PHATPhathom Pharmaceuticals INCStock-Other1.23%-0.66%—
24BCYCBicycle Therapeutics Plc-adrStock-Other1.22%-0.70%+0.19%
25CMPSCompass Pathways PLCStock-Other1.18%+1.18%NEW
26PACBPacific Biosciences Of CalifStock-Other1.13%+0.58%+200.00%
27CYTKCytokinetics INCStock-Healthcare1.13%——
28CORTCorcept Therapeutics INCStock-Healthcare1.08%-0.29%-29.76%
29VERAVera Therapeutics INCStock-Other1.01%-0.29%—
30ALKSAlkermes plcStock-Healthcare1.01%——
31✓ Engene Holdings INCStock-Other0.97%+0.97%NEW
32QUREuniQure N.V.Stock-Other0.94%+0.51%+227.06%
33ZBIOZenas Biopharma INCStock-Other0.78%+0.78%NEW
34QDELUSDQuidelortho CORPStock-Other0.77%-0.44%+13.78%
35FHTXFoghorn Therapeutics INCStock-Other0.77%——
36RAREUltragenyx Pharmaceutical InStock-Other0.74%——
37XENEXenon Pharmaceuticals INCStock-Other0.70%——
384XC1Kalvista Pharmaceuticals INCStock-Other0.65%——
39IMNMImmunome INCStock-Other0.62%-1.01%-61.54%
40FCXFreeport-mcmoran INCStock-Materials0.60%—-0.03%
41AXSMAxsome Therapeutics INCStock-Healthcare0.58%—-1.01%
42BIIBBiogen INCStock-Healthcare0.52%+0.52%NEW
43LPCNLipocine INCStock-Other0.51%+0.51%NEW
44TVTXTravere Therapeutics INCStock-Other0.49%-0.47%-32.09%
45HROWHarrow INCStock-Other0.48%-0.50%-29.41%
46PHVSPharvaris N.V.Stock-Other0.48%——
47VSTMVerastem INCStock-Other0.45%——
48APGEApogee Therapeutics INCStock-Other0.43%-0.28%-43.75%
49HALOHalozyme Therapeutics INCStock-Healthcare0.37%——
50BBIOBridgebio Pharma INCStock-Healthcare0.37%——
1–50 of 73

Holding changes this quarter

Birchview Capital, LP's most significant position changes for 2026-03-31: Sold out: Amicus Therapeutics INC (AM6); New buy: Relmada Therapeutics INC (RLMD); New buy: Ocular Therapeutix INC (OCUL); New buy: Celldex Therapeutics INC (CLDX); New buy: Compass Pathways PLC (CMPS).

Position changes disclosed by Birchview Capital, LP for the quarter ending 2026-03-31, including ticker, issuer, weight change, shares change, and action
#TickerIssuerWeight ChangeShares ChangeAction
1NTLAIntellia Therapeutics INC+1.6%+41.22%Add
2✓ Biodesix INC+1.2%—Unchanged
3OVVOvintiv INC+1.2%—Unchanged
4KLACKla CORP+1.1%-9.14%Trim
5BMYBristol-myers Squibb Co+1%+1.13%Add
6UTHRUnited Therapeutics CORP+0.7%+50.00%Add
7PACBPacific Biosciences Of Calif+0.6%+200.00%Add
8QUREuniQure N.V.+0.5%+227.06%Add
9NKTRNektar Therapeutics+0.5%—Unchanged
10LRCXLam Research CORP+0.3%-10.73%Trim
11SLDBSolid Biosciences INC+0.2%-11.33%Trim
12GOSSGossamer Bio INC-0.3%-86.85%Trim
13APGEApogee Therapeutics INC-0.3%-43.75%Trim
14VERAVera Therapeutics INC-0.3%—Unchanged
15CORTCorcept Therapeutics INC-0.3%-29.76%Trim
16QDELUSDQuidelortho CORP-0.4%+13.78%Add
17TVTXTravere Therapeutics INC-0.5%-32.09%Trim
18HROWHarrow INC-0.5%-29.41%Trim
19ACADAcadia Pharmaceuticals INC-0.5%—Unchanged
20CMPXCompass Therapeutics INC-0.6%-7.98%Trim
21PHATPhathom Pharmaceuticals INC-0.7%—Unchanged
22BCYCBicycle Therapeutics Plc-adr-0.7%+0.19%Add
23PTGXProtagonist Therapeutics INC-0.7%-36.36%Trim
24GPCRStructure Therapeutics INC-0.9%+11.11%Add
25STOKStoke Therapeutics INC-0.9%-19.23%Trim
26IMNMImmunome INC-1%-61.54%Trim
27PHRPhreesia INC-1%-87.08%Trim
28CSTLCastle Biosciences INC-1.7%-84.00%Trim
29OLMAOlema Pharmaceuticals INC-2.1%-18.59%Trim
30AM6Amicus Therapeutics INC—EXITSold out
31RLMDRelmada Therapeutics INC—NEWNew buy
32OCULOcular Therapeutix INC—NEWNew buy
33CLDXCelldex Therapeutics INC—NEWNew buy
34CMPSCompass Pathways PLC—NEWNew buy
35✓ Engene Holdings INC—NEWNew buy
36ZBIOZenas Biopharma INC—NEWNew buy
37MASI*Masimo CORP—EXITSold out
38TXG10x Genomics Inc-class A—EXITSold out
39BIIBBiogen INC—NEWNew buy
40VTYXUSDVentyx Biosciences INC—EXITSold out
41LPCNLipocine INC—NEWNew buy
42ILMNIllumina INC—EXITSold out
43BHVNBiohaven Ltd.—EXITSold out
44IDYAIdeaya Biosciences INC—NEWNew buy
45RCUSArcus Biosciences INC—NEWNew buy
46TMCITreace Medical Concepts INC—EXITSold out
47RGNXRegenxbio INC—NEWNew buy
48RAPTRapt Therapeutics INC—EXITSold out
49KPTIEURKaryopharm Therapeutics INC—NEWNew buy
50RCKTRocket Pharmaceuticals INC—NEWNew buy

FAQ

What is Birchview Capital, LP and what type of investor is it?
Birchview Capital, LP is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $175.7M, spread across 73 disclosed positions.
What are Birchview Capital, LP's largest equity positions?
Based on the latest 13F filing, Birchview Capital, LP's top holdings by market value are: 1. Kla CORP (KLAC) — $29.3M (16.7%) 2. Bristol-myers Squibb Co (BMY) — $18.6M (10.6%) 3. Compass Therapeutics INC (CMPX) — $7.8M (4.4%) 4. Lam Research CORP (LRCX) — $7.7M (4.4%) 5. Stoke Therapeutics INC (STOK) — $6.8M (3.9%)
What changes did Birchview Capital, LP make in its most recent portfolio filing?
In the latest reported quarter, Birchview Capital, LP made 44 notable position adjustments: 13 new positions were initiated, 8 existing holdings were added to, 15 positions were partially reduced, and 8 were completely exited. The largest of these moves: Sold out: Amicus Therapeutics INC (AM6); New buy: Relmada Therapeutics INC (RLMD); New buy: Ocular Therapeutix INC (OCUL); New buy: Celldex Therapeutics INC (CLDX); New buy: Compass Pathways PLC (CMPS)
What sectors does Birchview Capital, LP focus on?
Birchview Capital, LP is concentrated in the following sectors based on its current disclosed equity portfolio: • Health Care: 46.0% • Information Technology: 42.8% • Energy: 9.9% • Materials: 1.2%

Peer Institutions

Institutions with a similar AUM

RW

Resolute Wealth Advisor, INC.

Total reported value

$175.7M

94 stks

2026-03-31

Concentration15.9
Portfolio Stability0.0
Sector conviction100.0

AUM within 0.0% of this institution

View detail
CW

Catamount Wealth Management

Total reported value

$175.7M

192 stks

2019-03-31

Concentration26.3
Portfolio Stability21.4
Sector conviction74.8

AUM within 0.0% of this institution

View detail
BA

Boyar Asset Management INC.

Total reported value

$175.7M

78 stks

2026-03-31

Concentration13.3
Portfolio Stability25.1
Sector conviction51.4

AUM within 0.0% of this institution

View detail

Similar Holdings Style

Institutions with overlapping top holdings

OC

Oaktop Capital Management Ii, L.p.

Total reported value

$1.3B

14 stks

2026-03-31

Concentration100.0
Portfolio Stability17.6
Sector conviction100.0

3 of the top 5 holdings overlap, including Lam Research CORP

View detail
WC

Wedge Capital Management L L P/nc

Total reported value

$6.1B

484 stks

2026-06-30

Concentration2.9
Portfolio Stability38.8
Sector conviction58.7

2 of the top 5 holdings overlap, including Kla CORP

View detail
AD

Albert D Mason INC

Total reported value

$154.5M

129 stks

2026-03-31

Concentration5.5
Portfolio Stability25.7
Sector conviction46.7

2 of the top 5 holdings overlap, including Kla CORP

View detail